Cyclosporine
Active ingredient: Cyclosporine
In short: Cyclosporine oral solution, USP MODIFIED is indicated for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants. Cyclosporine oral solution, USP MODIFIED has been used in combination with azathioprine and corticosteroids.
What is Cyclosporine used for?
Cyclosporine oral solution, USP MODIFIED is indicated for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants. Cyclosporine oral solution, USP MODIFIED has been used in combination with azathioprine and corticosteroids.
Cyclosporine oral solution, USP MODIFIED is indicated for the treatment of patients with severe active, rheumatoid arthritis where the disease has not adequately responded to methotrexate. Cyclosporine oral solution, USP MODIFIED can be used in combination with methotrexate in rheumatoid arthritis patients who do not respond adequately to methotrexate alone.
Cyclosporine oral solution, USP MODIFIED is indicated for the treatment of adult, nonimmunocompromised patients with severe (i.e., extensive and/or disabling), recalcitrant, plaque psoriasis who have failed to respond to at least one systemic therapy (e.g., PUVA, retinoids, or methotrexate) or in patients for whom other systemic therapies are contraindicated, or cannot be tolerated.
While rebound rarely occurs, most patients will experience relapse with cyclosporine oral solution, USP MODIFIED as with other therapies upon cessation of treatment.
âš Boxed warning (FDA's strongest warning)
Cyclosporine, the active ingredient of cyclosporine oral solution, USP MODIFIED, can cause nephrotoxicity and hepatotoxicity. The risk increases with increasing doses of cyclosporine. Renal dysfunction including structural kidney damage is a potential consequence of cyclosporine oral solution, USP MODIFIED and therefore renal function must be monitored during therapy. Care should be taken in using cyclosporine with nephrotoxic drugs .
Patients receiving cyclosporine oral solution, USP MODIFIED require frequent monitoring of serum creatinine . Elderly patients should be monitored with particular care, since decreases in renal function also occur with age. If patients are not properly monitored and doses are not properly adjusted, cyclosporine therapy can be associated with the occurrence of structural kidney damage and persistent renal dysfunction.
An increase in serum creatinine and BUN may occur during cyclosporine oral solution, USP MODIFIED therapy and reflect a reduction in the glomerular filtration rate. Impaired renal function at any time requires close monitoring, and frequent dosage adjustment may be indicated. The frequency and severity of serum creatinine elevations increase with dose and duration of cyclosporine therapy. These elevations are likely to become more pronounced without dose reduction or discontinuation. …
Cyclosporine dosage
Cyclosporine oral solution, USP MODIFIED has increased bioavailability in comparison to Sandimmune (cyclosporine oral solution, USP). Cyclosporine oral solution, USP MODIFIED and Sandimmune (cyclosporine oral solution, USP) are not bioequivalent and cannot be used interchangeably without physician supervision.
The daily dose of cyclosporine oral solution, USP MODIFIED should always be given in two divided doses (BID). It is recommended that cyclosporine oral solution, USP MODIFIED be administered on a consistent schedule with regard to time of day and relation to meals. Grapefruit and grapefruit juice affect metabolism, increasing blood concentration of cyclosporine, thus should be avoided.
Specific Populations
Renal Impairment in Kidney, Liver, and Heart Transplantation
Cyclosporine undergoes minimal renal elimination and its pharmacokinetics do not appear to be significantly altered in patients with end-stage renal disease who receive routine hemodialysis treatments . However, due to its nephrotoxic potential , careful monitoring of renal function is recommended; cyclosporine dosage should be reduced if indicated .
Renal Impairment in Rheumatoid Arthritis and Psoriasis
Patients with impaired renal function should not receive cyclosporine .
Hepatic Impairment
The clearance of cyclosporine may be significantly reduced in severe liver disease patients . Dose reduction may be necessary in patients with severe liver impairment to maintain blood concentrations within the recommended target range .
Newly Transplanted Patients
The initial oral dose of cyclosporine oral solution, USP MODIFIED can be given 4 to 12 hours prior to transplantation or be given postoperatively. The initial dose of cyclosporine oral solution, USP MODIFIED varies depending on the transplanted organ and the other immunosuppressive agents included in the immunosuppressive protocol. In newly transplanted patients, the initial oral dose of cyclosporine oral solution, MODIFIED is the same as the initial oral dose of Sandimmune (cyclosporine oral solution, USP). Suggested initial doses are available from the results of a 1994 survey of the use of Sandimmune (cyclosporine oral solution, USP) in US transplant centers. The mean ± SD initial doses were 9 ± 3 mg/kg/day for renal transplant patients (75 centers), 8 ± 4 mg/kg/day for liver transplant patients (30 centers), and 7 ± 3 mg/kg/day for heart transplant patients (24 centers). Total daily doses were divided into two equal daily doses. The cyclosporine oral solution, USP MODIFIED dose is subsequently adjusted to achieve a pre-defined cyclosporine blood concentration . …
Warnings & precautions
Do not take this medicine if: Cyclosporine oral solution, USP MODIFIED is contraindicated in patients with a hypersensitivity to cyclosporine or to any of the ingredients of the formulation.
Rheumatoid arthritis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine oral solution, USP MODIFIED.
Psoriasis patients who are treated with cyclosporine oral solution, USP MODIFIED should not receive concomitant PUVA or UVB therapy, methotrexate or other immunosuppressive agents, coal tar or radiation therapy. Psoriasis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine oral solution, USP MODIFIED.
Cyclosporine is the active ingredient of cyclosporine oral solution, USP MODIFIED. Hypertension is a common side effect of cyclosporine therapy which may persist . Mild or moderate hypertension is encountered more frequently than severe hypertension and the incidence decreases over time. In recipients of kidney, liver, and heart allografts treated with cyclosporine, antihypertensive therapy may be required . However, since cyclosporine may cause hyperkalemia, potassium-sparing diuretics should not be used. While calcium antagonists can be effective agents in treating cyclosporine-associated hypertension, they can interfere with cyclosporine metabolism .
During treatment with cyclosporine, vaccination may be less effective; and the use of live attenuated vaccines should be avoided.
Before initiating treatment, a careful physical examination, including blood pressure measurements (on at least two occasions) and two creatinine levels to estimate baseline should be performed. Blood pressure and serum creatinine should be evaluated every 2 weeks during the initial 3 months and then monthly if the patient is stable. …
Cyclosporine side effects
The principal adverse reactions of cyclosporine therapy are renal dysfunction, tremor, hirsutism, hypertension, and gum hyperplasia.
Hypertension, which is usually mild to moderate, may occur in approximately 50% of patients following renal transplantation and in most cardiac transplant patients.
Glomerular capillary thrombosis has been found in patients treated with cyclosporine and may progress to graft failure. The pathologic changes resembled those seen in the hemolytic-uremic syndrome and included thrombosis of the renal microvasculature, with platelet-fibrin thrombi occluding glomerular capillaries and afferent arterioles, microangiopathic hemolytic anemia, thrombocytopenia, and decreased renal function. Similar findings have been observed when other immunosuppressives have been employed post-transplantation.
Hypomagnesemia has been reported in some, but not all, patients exhibiting convulsions while on cyclosporine therapy. Although magnesium-depletion studies in normal subjects suggest that hypomagnesemia is associated with neurologic disorders, multiple factors, including hypertension, high dose methylprednisolone, hypocholesterolemia, and nephrotoxicity associated with high plasma concentrations of cyclosporine appear to be related to the neurological manifestations of cyclosporine toxicity. …
About this medicine
Cyclosporine oral solution, USP MODIFIED is an oral formulation of cyclosporine, USP that immediately forms an emulsion in an aqueous environment.
Cyclosporine, USP, the active principle in cyclosporine oral solution, USP MODIFIED, is a cyclic polypeptide immunosuppressant agent consisting of 11 amino acids. It is produced as a metabolite by the fungus species Tolypocladium inflatum.
Chemically, cyclosporine, USP is designated as [R-[R*,R*-(E)]]-cyclic-(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-3-hydroxy-N,4-dimethyl-L-2-amino-6-octenoyl-L-α-amino-butyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl) and has the following structural formula:
Each mL of cyclosporine oral solution, USP MODIFIED contains 100 mg/mL cyclosporine, USP and 15.3% v/v (12.18% wt/vol) dehydrated alcohol, USP and has the following inactive ingredients: polyoxyl 40 hydrogenated castor oil, polyglycerol (3) oleate and polyglycerol (10) oleate. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID f3dc2a50-1084-4190-a6f3-37034a04db86. Read the full official label on DailyMed.
Related medicines
Gabapentin Meloxicam Acetaminophen and Hydrocodone Duloxetine Prednisone Ibuprofen Tramadol Cyclobenzaprine